Hikma Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Hikma Pharmaceuticals est Riad Mishlawi, nommé en Sep2023, a un mandat de 1.17 ans. La rémunération annuelle totale est $ 1.55M, composée du salaire de 21.5% et des bonus 78.5%, y compris les actions et options de la société. détient directement 0.06% des actions de la société, d'une valeur de € 3.14M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.2 ans et 5.4 ans.

Informations clés

Riad Mishlawi

Directeur général

US$1.6m

Rémunération totale

Pourcentage du salaire du PDG	21.5%
Durée du mandat du directeur général	1.2yrs
Propriété du PDG	0.06%
Durée moyenne d'occupation des postes de direction	1.2yrs
Durée moyenne du mandat des membres du conseil d'administration	5.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Riad Mishlawi a-t-elle évolué par rapport aux bénéfices de Hikma Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$285m
Mar 31 2024	n/a	n/a	US$238m
Dec 31 2023	US$2m	US$333k	US$190m

Rémunération vs marché: La rémunération totale de Riad ($USD 1.55M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 3.48M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Riad avec les performances de l'entreprise.

PDG

Riad Mishlawi (60 yo)

1.2yrs

Titularisation

US$1,552,833

Compensation

Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Said Samih Darwazah	Executive Chairman	17.3yrs	US$3.57m	0.38% € 20.1m
Riad Mishlawi	CEO & Director	1.2yrs	US$1.55m	0.060% € 3.1m
Mazen Samih Darwazah	Executive Vice Chairman & President of MENA	19.2yrs	US$2.84m	0.63% € 32.8m
Khalid Waleed Al Nabilsi	Chief Financial Officer	13.8yrs	pas de données	0.20% € 10.6m
Patricia Bousfield	Chief Information Officer	no data	pas de données	pas de données
Guy Featherstone	Associate Director of Investor Relations	no data	pas de données	pas de données
Samuel Park	General Counsel	no data	pas de données	pas de données
Bassam Wael Kanaan	Executive Vice President of Corporate Development and M&A	10.7yrs	pas de données	0.26% € 13.5m
Hussein Arkhagha	Chief People Officer	1.2yrs	pas de données	pas de données
Susan Ringdal	Executive Vice President of Strategic Planning & Global Affairs	6.8yrs	pas de données	pas de données
William Larkins	President of Injectables Business	1.2yrs	pas de données	pas de données
Julie Hill	Senior Vice President of Corporate Quality Compliance/Health & Safety	less than a year	pas de données	pas de données

1.2yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de H5P n'est pas considérée comme expérimentée (ancienneté moyenne 1.2 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Said Samih Darwazah	Executive Chairman	17.3yrs	US$3.57m	0.38% € 20.1m
Riad Mishlawi	CEO & Director	1.2yrs	US$1.55m	0.060% € 3.1m
Mazen Samih Darwazah	Executive Vice Chairman & President of MENA	19.2yrs	US$2.84m	0.63% € 32.8m
Victoria Hull	Senior Independent Non-Executive Director	2yrs	US$149.27k	pas de données
Mary Henderson	Independent Non-Executive Director	8.1yrs	US$176.38k	0.0032% € 167.1k
John Castellani	Independent Non-Executive Director	8.7yrs	US$159.69k	0.0016% € 82.5k
Mohammed Ali Khaldoun Al-Husry	Non-Executive Director	19.1yrs	US$116.72k	0.52% € 27.4m
Douglas Hurt	Independent Non-Executive Director	4.5yrs	US$149.85k	0.0020% € 106.0k
Deneen Vojta	Independent Non-Executive Director	2yrs	US$127.05k	0.00045% € 23.5k
Cynthia Flowers	Independent Non-Executive Director	5.4yrs	US$134.68k	0.00050% € 26.1k
Nabil Rizk	Chairman of West-ward Pharmaceuticals	no data	pas de données	pas de données
Laura Balan	Independent Non-Executive Director	2.1yrs	US$124.98k	pas de données

5.4yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de H5P sont considérés comme expérimentés (ancienneté moyenne 5.4 ans).

Hikma Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Insider recently sold €1.0m worth of stock

Hikma Pharmaceuticals PLC Announces Executive Changes

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Insider recently sold €631k worth of stock

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

Recent updates

Hikma Pharmaceuticals plc Announces the Shelf-Life Extension of KLOXXADO Nasal Spray 8mg from 24 to 36 Months

Insider recently sold €1.0m worth of stock

First half dividend of US$0.32 announced

First half 2024 earnings released: EPS: US$1.02 (vs US$0.59 in 1H 2023)

Hikma Pharmaceuticals PLC Revises Group Earnings Guidance for the Full Year of 2024

Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024

Hikma Pharmaceuticals PLC Announces Executive Changes

Upcoming dividend of US$0.47 per share

Now 22% undervalued

Final dividend of US$0.47 announced

Full year 2023 earnings released: EPS: US$0.86 (vs US$0.84 in FY 2022)

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 25, 2024

Hikma Announces US Launch of COMBOGESIC IV

Hikma Pharmaceuticals PLC Announces Company Secretary Change

Hikma Pharmaceuticals PLC to Report First Half, 2024 Results on Aug 08, 2024

Hikma Pharmaceuticals PLC Provides Earnings Guidance for the Year 2023

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 250 Index

Now 20% undervalued

New minor risk - Insider selling

Insider recently sold €631k worth of stock

Now 20% undervalued

Hikma Pharmaceuticals PLC Appoints Bill Larkins as President of Its Injectables Business, Effective 1 September 2023

New minor risk - Dividend sustainability

First half 2023 earnings released: EPS: US$0.59 (vs US$0.76 in 1H 2022)

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Now 21% undervalued

Hikma Exceeds 150 Injectable Medicines in the US with Launch of Dobutamine Injection, USP

Now 20% undervalued

Now 21% undervalued

Upcoming dividend of US$0.37 per share at 2.7% yield

Now 20% undervalued

Full year 2022 earnings released: EPS: US$0.84 (vs US$1.82 in FY 2021)

Now 21% undervalued

Hikma Launches Authorized Generic of Xyrem® (Sodium Oxybate) in the US

Hikma Pharmaceuticals PLC to Report Fiscal Year 2022 Results on Feb 23, 2023

Hikma Pharmaceuticals PLC Appoints Deneen Vojta as Director

Hikma Pharmaceuticals PLC Announces Board Appointments

Hikma Pharmaceuticals PLC(LSE:HIK) dropped from FTSE 100 Index

Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., Launches RYALTRIS in US

Upcoming dividend of US$0.19 per share

First half 2022 earnings released

Hikma Pharmaceuticals plc Recommends Interim Dividend, Payable on 19 September 2022

Insufficient new directors

Insufficient new directors

Hikma Pharmaceuticals plc Announces Company Secretary Change

Hikma Pharmaceuticals PLC Announces Chief Executive Officer Changes

Hikma Pharmaceuticals PLC Approves Final Dividend for the Year 2021

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Custopharm Inc. from Water Street Healthcare Partners, LLC.

Upcoming dividend of US$0.36 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hikma Pharmaceuticals PLC (LSE:HIK) announces an Equity Buyback for £300 million worth of its shares.

Hikma Pharmaceuticals PLC Provides Revenue Guidance for 2022

Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.

Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Custopharm Inc. from Water Street Healthcare Partners, LLC for approximately $430 million.

Upcoming dividend of US$0.18 per share

First half 2021 earnings released: EPS US$1.07 (vs US$0.88 in 1H 2020)

Hikma Pharmaceuticals PLC Announces US FDA Approval of KLOXXADO

New 90-day low: €25.80

Full year 2020 earnings released: EPS US$1.83 (vs US$2.01 in FY 2019)

Revenue beats expectations

Hikma Pharmaceuticals PLC, Annual General Meeting, Apr 23, 2021

Eyevance Pharmaceuticals Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Hikma Pharmaceuticals PLC to Report Fiscal Year 2020 Results on Feb 25, 2021

New 90-day low: €26.40

Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited.

Hikma Pharmaceuticals PLC Provides Update on Generic Advair Diskus®

Hikma Pharmaceuticals PLC Launches Generic Advair Diskus®